Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of clonidine vs clonidine + oxybutynin for sialorrhoea in Parkinson's disease
2007-004654-81Phase 2Terminated
- Sponsor
- Summit Therapeutics
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of clonidine and oxybutynin in hypersalivation (2 arms), sponsored by Summit Therapeutics. Primary endpoint: Saliva excretion rates. Started Oct 2007; status: terminated.
02
Drugs
clonidineoxybutynin
03
Conditions
hypersalivation
Beyond the preview
Go deeper on 2007-004654-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004654-81.